Drugs / Teceleukin
Teceleukin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05608148 Background | Oct 2022 → Aug 2027 expected | childhood malignant neoplasm, neuroblastoma | Kyushu University | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Teceleukin | “Teceleukin: 750,000 units/m2/day on Day29-31 and 1,000,000 units/m2/day on Day 36- 39” NCT05608148 ↗ |
| Known as | BG 8301 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107892 ↗ |
| Known as | Imunace | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107892 ↗ |
| Known as | Interleukin-2 teceleukin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107892 ↗ |
| Known as | RO 23-6019 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107892 ↗ |
| Known as | Teceleukina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107892 ↗ |
| Known as | Teceleukine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107892 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2107892 ↗ |